iifl-logo

Granules India Ltd Historical Data

Add as a Preferred Source on Google
₹868.65
(1.83%)
Sep 25, 2026|03:58:49 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.

Granules India Ltd Historical Data

25/08/2026calendar-icon
25/09/2026calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

26-Aug-2026

849.95

851.75821.85828.233,00950,65,64,802.553,59,978

27-Aug-2026

828.2

848824.55832.331,43393,98,34,623.256,26,829

28-Aug-2026

833.5

844.75833.5836.6514,83127,52,46,239.22,28,369

31-Aug-2026

832.5

840.65823828.533,08665,24,28,921.44,59,281

01-Sep-2026

828.5

840.9824.1837.224,97428,78,81,541.251,69,105

02-Sep-2026

834.05

838816831.7526,03365,24,59,874.83,31,695

03-Sep-2026

837.5

873.5834853.8564,0792,41,44,44,491.212,52,531

04-Sep-2026

853

863.6838.6848.327,02599,47,32,689.55,59,829

07-Sep-2026

844.5

873.85842.2867.331,32289,42,94,494.755,05,075

08-Sep-2026

869

899.85865895.3564,0681,87,09,84,725.958,73,716

09-Sep-2026

899.75

901.8878.1884.849,8381,25,03,68,919.258,59,427

10-Sep-2026

870.1

905.85870.1899.2571,4031,42,60,62,485.36,92,743

11-Sep-2026

895.95

914.85881.25909.31,32,3817,02,97,31,962.6548,39,089

15-Sep-2026

917

923.65872.5872.664,7301,86,31,25,408.2511,33,539

16-Sep-2026

869

872829835.668,1212,24,85,49,165.214,18,384

17-Sep-2026

841

874838.2870.432,81978,93,81,177.854,36,081

18-Sep-2026

874

890.4865.9875.541,5551,05,41,66,951.16,47,972

21-Sep-2026

879.25

890.3871875.1525,57052,45,77,200.82,80,831

22-Sep-2026

876

876.6853.9864.0520,31255,27,53,6252,54,781

23-Sep-2026

861.95

873.95857.35860.2518,11434,08,07,176.82,10,498

24-Sep-2026

857

867850.5585315,28128,04,53,864.91,59,996

Granules India: Related NEWS

Granules India Inaugurates Two Centres of Excellence at IIT Hyderabad to Boost R&D

These include the Ascelis Center of Excellence for Peptide Development and Characterization and the Granules Center of Excellence for Particle Engineering.

1 Dec 2025|12:38 PM
Read More
Top Stocks for Today - 23rd June 2025

Here are some of the stocks that may see significant price movement today.: Hindustan Aeronautics, BEL, Waaree Renewable, etc.

23 Jun 2025|08:36 AM
Read More
Granules India Wraps Up USFDA Inspection at Bonthapally with Single Observation

The five-day inspection ran from June 16 to June 20, 2025

20 Jun 2025|07:00 PM
Read More
Granules India Q4 Net Profit Rises 18% YoY to ₹152 Crore

The firm’s net debt fell by ₹136 crore to ₹706.1 crore, with a comfortable net debt-to-EBITDA at 0.75x

29 May 2025|11:07 AM
Read More
LIC Increases Stake in Granules India to 5.02%

The pharma company caters to various international markets, reinforcing its position as a key player in the pharmaceutical industry.

4 Mar 2025|09:37 PM
Read More
Granules India’s Gagillapur Facility Receives USFDA Warning Letter

Granules India, maintaining that it fully intends to respond in the time period allowed, as well as requesting a meeting with the FDA to show progress made in compliance, has taken care to make this clear as well.

27 Feb 2025|11:16 PM
Read More
Granules India Secures USFDA Approval for Andhra Facility

The inspection covered Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs) for oncology and non-oncology segments, underscoring the plant’s adherence to high manufacturing standards.

12 Nov 2024|10:14 AM
Read More
Granules India Secures USFDA Nod for Bupropion SR Tablets

Bupropion hydrochloride is widely prescribed for treating major depressive disorder (MDD) and preventing seasonal affective disorder (SAD).

20 Oct 2024|07:33 PM
Read More
Granules India’s Gagilapur unit gets 6 observations from USFDA

The USFDA has also noted a repeat observation from the company's January 2023 inspection.

12 Sep 2024|03:26 PM
Read More
Granules India Gets USFDA Nod for Pediatric Glycopyrrolate Oral Solution

Glycopyrrolate Oral Solution is an anticholinergic medication used to treat pediatric patients aged 3 to 16 years with neurological conditions that cause drooling.

21 Aug 2024|03:13 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.